TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18974539

Group type: EXPERIMENTAL
Intervention: 1% povidone-iodine mouth rinse
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouth rinse
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo mouth rinse
Number of subjects: 45
Study: 15802780

Group type: EXPERIMENTAL
Intervention: Active vitamin D metabolite
Number of subjects: 0
Study: 11845758

Group type: EXPERIMENTAL
Intervention: CathSim Intravenous Training System (CathSim ITS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Plastic arm (control group)
Number of subjects: 28
Study: 10502570

Group type: EXPERIMENTAL
Intervention: 0.1% sodium hyaluronate solution (Fermavisc)
Number of subjects: 70

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 70
Study: 7570720

Group type: EXPERIMENTAL
Intervention: Three-dimensional TOF MRA
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Two-dimensional TOF MRA
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Duplex Ultrasonography (DU)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Combined use of three-dimensional TOF MRA and DU
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Angiography (MRA)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Contrast Arteriography (CA)
Number of subjects: 176
Study: 2407875

Group type: EXPERIMENTAL
Intervention: Dietary intervention with reduced total and saturated fat intake, substituting low-fat meats and dairy products for high-fat options.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group from the Cholesterol Lowering Atherosclerosis Study.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased intake of lauric, oleic, and linoleic acids.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary energy sources including protein, carbohydrate, alcohol, total fat, and polyunsaturated fat.
Number of subjects: 0
Study: 37879

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy for 12 weeks to reduce supine BP to 150/90 mmHg or below
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy for 12 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 24
Study: 31843386

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg per day from the second to the twentieth day after surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: No diuretic (control)
Number of subjects: 60
Study: 30744676

Group type: EXPERIMENTAL
Intervention: Acupuncture with Yishen Granule (YSG)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Acupuncture with placebo herbal medicine
Number of subjects: 240

Group type: COMPARATOR
Intervention: Sham acupuncture with YSG
Number of subjects: 240

Group type: COMPARATOR
Intervention: Sham acupuncture with placebo herbal medicine
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Acupuncture with YSG
Number of subjects: 240
Study: 29064991

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA
Number of subjects: 76

Group type: COMPARATOR
Intervention: OnabotulinumtoxinA / AbobotulinumtoxinA
Number of subjects: 76
Study: 26939322

Group type: EXPERIMENTAL
Intervention: Reducing technique with consciousness conduction involved (Group A)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Reducing technique with needle rotation (Group B)
Number of subjects: 108
Study: 23745725

Group type: EXPERIMENTAL
Intervention: ZrSiO4 -ceramic crowns
Number of subjects: 223

Group type: COMPARATOR
Intervention: Gold crowns
Number of subjects: 223
Study: 21344144

Group type: EXPERIMENTAL
Intervention: CMV-immunoglobulins (Cytotect Biotest) for 12 months and short Ganciclovir or Valganciclovir therapy from 21th to 42th postoperative day followed by acyclovir up to 24 months
Number of subjects: 57

Group type: COMPARATOR
Intervention: Acyclovir for 24 months
Number of subjects: 57
Study: 20329441

Group type: EXPERIMENTAL
Intervention: Naturo fruit bar (50 grams carbohydrate)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Glucose standard (50 grams carbohydrate)
Number of subjects: 11
Study: 17001146

Group type: EXPERIMENTAL
Intervention: Computer-based training
Number of subjects: 10

Group type: COMPARATOR
Intervention: Traditional trainer-based training
Number of subjects: 10
Study: 15210261

Group type: EXPERIMENTAL
Intervention: Cognitive group (12 min preparation with sensory and procedural information)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cognitive/behavioural group (cognitive preparation plus instruction in deep breathing exercises, tongue depressor task and swallowing technique)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 11171290

Group type: EXPERIMENTAL
Intervention: Oral continuous combined HRT (Kliogest(R); 2 mg of oestradiol + 1 mg of norethisterone)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 9632183

Group type: EXPERIMENTAL
Intervention: Intra-arterially administered papaverine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Medical management alone for vasospasm (Control)
Number of subjects: 31
Study: 8142195

Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg twice daily)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 3146197

Group type: EXPERIMENTAL
Intervention: L-asparaginase treatment
Number of subjects: 10
Study: 1415455

Group type: EXPERIMENTAL
Intervention: Topical fibronectin
Number of subjects: 272

Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 272

Group type: COMPARATOR
Intervention: Commercially available artificial tear
Number of subjects: 272
Study: 752876

Group type: EXPERIMENTAL
Intervention: Combination of VM‐26 and CCNU at full dose
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Combination of VM‐26 and CCNU (half dose) with daily intake of procarbazine for 20 days
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Radiotherapy after three cycles of chemotherapy
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Reduction in the dose of CCNU to 60 mg/m2 per cycle
Number of subjects: 71
Study: 31496440

Group type: EXPERIMENTAL
Intervention: Constraint-Induced Aphasia Therapy Plus (CIAT-Plus)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Multi-Modal Aphasia Treatment (M-MAT)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: CIAT-Plus and M-MAT
Number of subjects: 216
Study: 27894852

Group type: EXPERIMENTAL
Intervention: Warmed bupivacaine 0.5% (15mL at 37°C)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cold bupivacaine 0.5% (15mL at 13-15°C)
Number of subjects: 80
Study: 25544718

Group type: EXPERIMENTAL
Intervention: Paralympic-level ID sport footage and information
Number of subjects: 114

Group type: COMPARATOR
Intervention: Olympic footage and information
Number of subjects: 114
Study: 23604333

Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 22142713

Group type: EXPERIMENTAL
Intervention: Lumbar extension training with pelvic stabilization (STAB; n=15)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Lumbar extension training without pelvic stabilization (NO-STAB; n=15)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (n=12)
Number of subjects: 42
Study: 19520162

Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched yogurt drink
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Phytosterol consumption (test group)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No phytosterol consumption (control group)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Phytosterol consumption
Number of subjects: 12
Study: 17305708

Group type: EXPERIMENTAL
Intervention: Strength training (BR-Tr) with dynamic calf-raise and leg-press exercises
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (BR-Con) with no strength training
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups (BR-Con and BR-Tr)
Number of subjects: 12
Study: 14668275

Group type: EXPERIMENTAL
Intervention: High-fat meal (780 kcal)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-carbohydrate, high-fiber meal (780 kcal)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-carbohydrate, low-fiber meal (780 kcal)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nondiabetic subjects (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All meals
Number of subjects: 60
Study: 10955751

Group type: EXPERIMENTAL
Intervention: Peak expiratory flow monitoring with educational intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group with educational intervention and symptom-based self-management
Number of subjects: 100
Study: 8843633

Group type: EXPERIMENTAL
Intervention: PRP‐T and DTP vaccines combined in the same syringe
Number of subjects: 251

Group type: COMPARATOR
Intervention: PRP‐T and DTP vaccines given separately
Number of subjects: 251
Study: 1345953

Group type: EXPERIMENTAL
Intervention: 100 micrograms/ml rPDGF‐BB
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6374562

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 0.03%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate 0.1%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31456498

Group type: EXPERIMENTAL
Intervention: Lumacaftor/ivacaftor (LUM/IVA)
Number of subjects: 21
Study: 28637033

Group type: EXPERIMENTAL
Intervention: Orange juice rinsing (pH 3.8)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Water rinsing (pH 6.7)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both rinsing solutions
Number of subjects: 30
Study: 25489785

Group type: EXPERIMENTAL
Intervention: Rifapentine 10 mg/kg
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Rifapentine 15 mg/kg
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Rifapentine 20 mg/kg
Number of subjects: 334

Group type: COMPARATOR
Intervention: Rifampin 10 mg/kg (Control)
Number of subjects: 334
Study: 23850060

Group type: EXPERIMENTAL
Intervention: Insulin infusion during an insulin tolerance test (ITT)
Number of subjects: 8
Study: 21934055

Group type: EXPERIMENTAL
Intervention: Medication management plus CBT
Number of subjects: 124

Group type: COMPARATOR
Intervention: Medication management plus instructions in CBT
Number of subjects: 124

Group type: COMPARATOR
Intervention: Medication management only
Number of subjects: 124
Study: 19207734

Group type: EXPERIMENTAL
Intervention: Dietary diary method
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Duplicate plate method
Number of subjects: 12
Study: 16476920

Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg twice daily or once daily (with a 40-mg loading dose)
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg 4 times daily
Number of subjects: 829

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Valdecoxib
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 829
Study: 15248005

Group type: EXPERIMENTAL
Intervention: Montelukast sodium
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11284820

Group type: EXPERIMENTAL
Intervention: Vital View laryngoscope
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional metal fibrelight laryngoscope
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vital View laryngoscope with prevention of light emission from the side
Number of subjects: 100
Study: 9179510

Group type: EXPERIMENTAL
Intervention: 8 mg/day s.l. buprenorphine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Naloxone (10 mg 70 kg i.m.) during 8 mg buprenorphine maintenance
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo dosing after 8 or 16 mg s.l. buprenorphine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Buprenorphine maintenance (8 mg/day)
Number of subjects: 8
Study: 8144233

Group type: EXPERIMENTAL
Intervention: Cobalt chloride (soluble cobalt compound)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Cobalt oxide (insoluble cobalt compound)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cobalt in blood and urine (normal levels)
Number of subjects: 23
Study: 3513714

Group type: EXPERIMENTAL
Intervention: Salbutamol inhalation by rotahaler
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tilting the head back during inhalation and holding the breath for 10 seconds
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Rotahaler treatment
Number of subjects: 15
Study: 31269580

Group type: EXPERIMENTAL
Intervention: Combined treatment group (0.5% racanisodamine eyedrops twice a day during semesters, 1% atropine eyedrops before sleep during vacation)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Atropine group (1% atropine eyedrops before sleep every day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo group (no medication)
Number of subjects: 150
Study: 28490353

Group type: EXPERIMENTAL
Intervention: Scrolling layout of surveys
Number of subjects: 530

Group type: COMPARATOR
Intervention: Paging layout of surveys
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Both layouts (scrolling and paging)
Number of subjects: 530
Study: 26178508

Group type: EXPERIMENTAL
Intervention: 5-field dIMRT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 7-field dIMRT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 9-field dIMRT
Number of subjects: 30
Study: 22669334

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) at increasing doses (2 gr/day) for 5-15 days prior to surgical resection
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-treated control group of 6 patients
Number of subjects: 12
Study: 25155815

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy (CBT) for 9 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 19
Study: 19685520

Group type: EXPERIMENTAL
Intervention: Intracoronary bone marrow stem cell (BMSC) transfer at 4 to 7 days post-AMI
Number of subjects: 660

Group type: COMPARATOR
Intervention: Emergent transfer (within 24 hours post-AMI)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Intracoronary bone marrow stem cell (BMSC) therapy at 4 to 7 days
Number of subjects: 660
Study: 16508028

Group type: EXPERIMENTAL
Intervention: E-health innovations including videoconferencing, telephone, secure messaging (e-mail), and the Internet for psychiatric consultation-liaison service.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Successful models of service delivery used in suburban and urban settings.
Number of subjects: 0
Study: 15587828

Group type: EXPERIMENTAL
Intervention: 100g OGTT
Number of subjects: 248

Group type: COMPARATOR
Intervention: 75g OGTT
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Comparison of both OGTTs
Number of subjects: 248
Study: 10793164

Group type: EXPERIMENTAL
Intervention: 10 mg of oral xemilofiban
Number of subjects: 7232

Group type: EXPERIMENTAL
Intervention: 20 mg of oral xemilofiban
Number of subjects: 7232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7232
Study: 9395803

Group type: EXPERIMENTAL
Intervention: Pethidine 50 mg as a 1 ml injection 1 to 2 hours before operation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline 1 ml intramuscularly before operation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pethidine 50 mg as a 1 ml injection immediately after surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline 1 ml intramuscularly immediately after surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Total dose of pethidine given
Number of subjects: 40
Study: 7954480

Group type: EXPERIMENTAL
Intervention: Moclobemide 150 mg twice daily (b.i.d.)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Moclobemide 300 mg three-times-daily (t.i.d.)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Moclobemide 450 mg three-times-daily (t.i.d.)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Moclobemide 150 mg b.i.d. and t.i.d. groups
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 178
Study: 2955804

Group type: EXPERIMENTAL
Intervention: Fentanyl 15 micrograms kg-1
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5% Halothane
Number of subjects: 0
Study: 29305282

Group type: EXPERIMENTAL
Intervention: Hi Five Intervention
Number of subjects: 43
Study: 28736944

Group type: EXPERIMENTAL
Intervention: Acipimox treatment
Number of subjects: 8
Study: 26247037

Group type: EXPERIMENTAL
Intervention: Successful PTA group (58 patients)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Unsuccessful PTA group (75 patients)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (65 patients, with diabetes but no PAD)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Prothrombin allele G20210A
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: MTHFR 677 or 1298 alleles
Number of subjects: 198
Study: 23942527

Group type: EXPERIMENTAL
Intervention: Hybrid natural orifice translumenal endoscopic surgery (NOTES) colectomy (HNC)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional laparoscopic colectomy (CL)
Number of subjects: 70
Study: 21348024

Group type: EXPERIMENTAL
Intervention: Velband as tourniquet underpadding
Number of subjects: 100

Group type: COMPARATOR
Intervention: Limb drapes as underpadding
Number of subjects: 100
Study: 19058660

Group type: EXPERIMENTAL
Intervention: Race similarity (RS)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Proactivity
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Race similarity (RS) and Proactivity interaction
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Race-related fraternal relative deprivation (RD)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Roles in mentoring dyads
Number of subjects: 126
Study: 17156002

Group type: EXPERIMENTAL
Intervention: Curettage
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Cantharidin
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Salicylic acid and lactic acid
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Imiquimod
Number of subjects: 124
Study: 12681035

Group type: EXPERIMENTAL
Intervention: Electrocautery non-scalpel vasectomy (ENSV)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Marie Stopes scalpel vasectomy procedure
Number of subjects: 325
Study: 10736656

Group type: EXPERIMENTAL
Intervention: Ketac Molar
Number of subjects: 105

Group type: COMPARATOR
Intervention: Dyract
Number of subjects: 105
Study: 7483868

Group type: EXPERIMENTAL
Intervention: Hypocaloric nutrition (glucose or xylitol/sorbitol-amino acid solutions)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Xylitol/sorbitol solution
Number of subjects: 44
Study: 2090557

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (group A)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional therapy (group B)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Fast CKMB release group
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Reversibility observed in 21/62 patients (34%)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Patients not showing redistribution of thallium-201
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Fast CKMB release
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Slow CKMB release
Number of subjects: 62
Study: 376036

Group type: EXPERIMENTAL
Intervention: bromocriptine 2.5 mg twice daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 47
Study: 30651109

Group type: EXPERIMENTAL
Intervention: Actively trained classifiers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passively trained classifiers with computational adaptation in a virtual environment
Number of subjects: 0
Study: 28856940

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rGH) (0.4 mg injection daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study: 25997707

Group type: EXPERIMENTAL
Intervention: JE+rabies-accelerated (n = 217)
Number of subjects: 440

Group type: COMPARATOR
Intervention: JE-standard (n = 56)
Number of subjects: 440

Group type: COMPARATOR
Intervention: JE+rabies-standard (n = 167)
Number of subjects: 440
Study: 23789216

Group type: EXPERIMENTAL
Intervention: Qi-regulating, chest-relaxing and blood-activating therapy integrated with some Western Medicines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple and conventional Western Medicine alone
Number of subjects: 0
Study: 21479913

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg combined with vitamin D(3) 5,600 IU
Number of subjects: 515

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 515
Study: 18379369

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with reduced-dose carboplatin (AUC 3) and gemcitabine (1250 mg/m on days 1 and 8)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with gemcitabine and low-dose carboplatin
Number of subjects: 1
Study: 16824148

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) combined with medium-dose amphotericin B (AMB)
Number of subjects: 20
Study: 12615559

Group type: EXPERIMENTAL
Intervention: 5 mg of melatonin taken at bedtime for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Matching placebo taken at bedtime for 4 weeks
Number of subjects: 40
Study: 11789225

Group type: EXPERIMENTAL
Intervention: Combination therapy (Chinese herbal medicine combined with synchronous radio- and chemotherapy) in group A
Number of subjects: 134

Group type: COMPARATOR
Intervention: Synchronous radio- and chemotherapy in group B
Number of subjects: 134

Group type: COMPARATOR
Intervention: Non-synchronous radio- and chemotherapy in group C
Number of subjects: 134
Study: 9212969

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (Group H)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 8
Study: 8273637

Group type: EXPERIMENTAL
Intervention: IV glucagon (1 mg)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: 0.125 mg oral hyoscyamine sulfate
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: 0.25 mg oral hyoscyamine sulfate
Number of subjects: 349

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 349